Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TLR2 | O60603 | 3/20 | 0.58 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.56 |
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30885878 | 0.99 | KMT2A (0.58) | KMT2ATLR2TLR1MDM2KLK7 | |
| SCHEMBL2267346 | 0.99 | KMT2A (0.58) | KMT2ATLR2TLR1MDM2KLK7 | |
| SCHEMBL29401707 | 0.99 | KMT2A (0.58) | KMT2ATLR2TLR1MDM2KLK7 | |
| SCHEMBL999302 | 0.99 | KMT2A (0.58) | KMT2ATLR2TLR1MDM2KLK7 | |
| SCHEMBL12040103 | 0.99 | KMT2A (0.58) | KMT2ATLR2TLR1MDM2KLK7 | |
| SCHEMBL29362262 | 0.99 | KMT2A (0.58) | KMT2ATLR2TLR1MDM2KLK7 | |
| SCHEMBL25357595 | 0.96 | MDM2 (0.58) | KMT2ATLR2TLR1MDM2MDM4 | |
| SCHEMBL21009795 | 0.96 | MDM2 (0.58) | KMT2ATLR2TLR1MDM2MDM4 | |
| SCHEMBL4600483 | 0.96 | MDM2 (0.58) | KMT2ATLR2TLR1MDM2MDM4 | |
| SCHEMBL31714126 | 0.96 | MDM2 (0.58) | KMT2ATLR2TLR1MDM2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| EP-2147925-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2010-01-27 | — | — | EP | disclosed |
| EP-1656390-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | KMT2A 4429/4885TLR2 20/4885TLR1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.